<DOC>
	<DOCNO>NCT02675322</DOCNO>
	<brief_summary>Danlou tablets Chinese patent medicine approve China treatment ischemic heart disease , evidence support efficacy cardiac remodeling remain unclear . This pilot study design determine whether Danlou tablet reduce adverse left ventricular ( LV ) remodel patient acute myocardial infarction ( MI ) . Patients follow acute MI enrol randomly allocate Danlou tablet ( 4.5 g q.d . 90 day ) placebo , superimpose standard medication treatment MI . Major end point change LV volume ejection fraction evaluate serial echocardiography addition clinical outcome also determine .</brief_summary>
	<brief_title>Danlou Tablets Prevent Left Ventricular Remodeling</brief_title>
	<detailed_description>This randomize , prospective , double-blind , placebo-controlled , parallel-group clinical trial perform two institution ( Guangdong Provincial Hospital CM Wuyi Hospital CM ) . The study conduct accordance Declaration Helsinki text revision participant provide write informed consent enrollment . The Clinical Research Ethical Committee Guangdong Provincial Hospital Chinese Medicine approve research protocol ( B2011-41-01 ) . Once eligible candidate undergone PCI , admit coronary intensive care unit receive standard treatment accord institutional protocol base American College Cardiology/ American Heart Association European Society Cardiology guidelines.20 Simultaneously , patient randomize assigned 1:1 ratio receive Danlou tablet ( 4.5 g oral dose take daily ) match placebo 90 day accord computer-generated site-stratified , block randomization schedule . Danlou tablets approve China Food Drug Administration treatment ischemic heart disease 2005 ( Z20050244 ) .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Ventricular Remodeling</mesh_term>
	<criteria>acute myocardial infarction successfully underwent revascularization previous myocardial infarction within 30 day malignant arrhythmia congenital heart disease cardiac shock document suspected history heart failure depress LV ejection fraction &lt; 15 % plan coronary artery bypass graft life expectancy &lt; 1 year hepatic impairment glomerular filtration rate â‰¤30 mL/min per 1.73 m2 autoimmune connective tissue disease chronic substance abuse psychiatric illness unable complete 3 month clinical followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>